Press Releases Investors & News / Press Releases Year None2024202320222021202020192018201720162015201420132012201120102009 08/28/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September 08/06/24 Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update 08/06/24 Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors 07/23/24 Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 05/28/24 Exelixis to Present at the William Blair 44th Annual Growth Stock Conference 05/20/24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA 05/07/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May 04/30/24 Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update 04/16/24 Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 02/27/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March 02/06/24 Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update 02/01/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February 01/25/24 Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 01/23/24 Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 01/22/24 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 01/18/24 European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets 01/07/24 Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 01/02/24 Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Year None2024202320222021202020192018201720162015201420132012201120102009 08/28/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September 08/06/24 Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update 08/06/24 Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors 07/23/24 Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 05/28/24 Exelixis to Present at the William Blair 44th Annual Growth Stock Conference 05/20/24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA 05/07/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May 04/30/24 Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update 04/16/24 Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 02/27/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March 02/06/24 Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update 02/01/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February 01/25/24 Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 01/23/24 Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 01/22/24 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 01/18/24 European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets 01/07/24 Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 01/02/24 Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
08/06/24 Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
05/20/24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
02/06/24 Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
01/25/24 Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
01/23/24 Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
01/22/24 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
01/18/24 European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
01/07/24 Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
